Evidence map›Paper›PMID 30067989›Full record

ArticleCell reports2018

Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies.

Sandro Nuciforo, Isabel Fofana, Matthias S Matter, Tanja Blumer, Diego Calabrese, Tujana Boldanova, Salvatore Piscuoglio, Stefan Wieland, Femke Ringnalda, Gerald Schwank and 3 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06355700 (Hepatocellular Carcinoma Organoids to Explore Tumor Microenvironment and Test Treatment Efficacy - Hepatocellular Carcinoma Liver Organoids), which is not on this map. Cited by 290 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
290citing papers in PubMed, 5 pooled it
14.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06355700 naunknown statusnot on this mapstarted 2023, after this paper: background citation

Hepatocellular Carcinoma Organoids to Explore Tumor Microenvironment and Test Treatment Efficacy - Hepatocellular Carcinoma Liver Organoids (HELIO)

TypeinterventionalSponsorFondazione Policlinico Universitario Agostino Gemelli IRCCSRan2023 to 2025Enrolled10ConditionsHepatocellular CarcinomaArmsLiver biopsy
3 · Its place in the literature

Who cites it

290 citing papers in PubMed, 5 syntheses or guidelines pooled it, 456 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. [Study on F9 gene expression downregulation and its clinical value in hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023
    Pooled it
  4. Guideline
  5. Pooled it
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

230 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Sandro NuciforoDepartment of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Isabel FofanaDepartment of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Matthias S MatterInstitute of Pathology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Tanja BlumerDepartment of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Diego CalabreseDepartment of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Tujana BoldanovaDepartment of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland; Clinic of Gastroenterology and Hepatology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Salvatore PiscuoglioInstitute of Pathology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Stefan WielandDepartment of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Femke RingnaldaInstitute of Molecular Health Sciences, ETH Zurich, Otto-Stern-Weg 7, HPL, 8093 Zürich, Switzerland.
Gerald SchwankInstitute of Molecular Health Sciences, ETH Zurich, Otto-Stern-Weg 7, HPL, 8093 Zürich, Switzerland.
Luigi M TerraccianoInstitute of Pathology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Charlotte K Y NgDepartment of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland; Institute of Pathology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Markus H HeimDepartment of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland; Clinic of Gastroenterology and Hepatology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland. Electronic address: markus.heim@unibas.ch.
University of Basel · CHUniversity Hospital of Basel · CHETH Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the second most frequent cause of cancer-related mortality worldwide. The multikinase inhibitor sorafenib is the only treatment option for advanced HCC. Due to tumor heterogeneity, its efficacy greatly varies between patients and is limited due to adverse effects and drug resistance. Current in vitro models fail to recapitulate key features of HCCs. We report the generation of long-term organoid cultures from tumor needle biopsies of HCC patients with various etiologies and tumor stages. HCC organoids retain the morphology as well as the expression pattern of HCC tumor markers and preserve the genetic heterogeneity of the originating tumors. In a proof-of-principle study, we show that liver cancer organoids can be used to test sensitivity to sorafenib. In conclusion, organoid models can be derived from needle biopsies of liver cancers and provide a tool for developing tailored therapies.

Indexed as

AgedAged, 80 and overAnimalsCarcinoma, HepatocellularCells, CulturedFemaleHumansLiver NeoplasmsMaleMiceMiddle AgedOrganoidsTissue Culture TechniquesBiobankcholangiocellular carcinomadrug responsegenetic heterogeneityhepatocellular carcinomaliverneedle biopsypatient-derived organoidspatient-derived xenografts

Identifiers

PMID30067989
PMCPMC6088153
OpenAlexW2887409499

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.